Drug recall · September 14, 2016
ARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL recall
Why: CGMP Deviations
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
ARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL (1 mg/mL) , Rx Only, Manufactured in Hungary for TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC# 0703-0020-31 (Single Use Bag), NDC # 0703-0020-32 (5 Single Use Bags in One Carton).
- Lots / codes
All lots within Expiry. Lot # 4720915, 6790315, 6800315, 6810315, 6820315
- Quantity
- 1,299 bags
- Company
- Teva North America, Horsham, PA
- Distribution
- Nationwide and Puerto Rico
- Initiated
- June 17, 2016 · Voluntary: Firm initiated
- Classified
- September 7, 2016
- Reported
- September 14, 2016
- Ended
- February 7, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Argatroban
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.